R. Jacob Vogelstein

Director at NextPoint Therapeutics.

Raised on NextPoint Therapeutics filings

$33.7M

of $48.7M offered across 1 Form D filing

Form D filings: 1
Teammates: 7
Last filing: Jul 30, 2026

Company

NextPoint Therapeutics

Biotech · Cambridge, MA

Antibodies against the B7-H7 checkpoint in cancer

Antibodies against the B7-H7 checkpoint in cancer

Investors: 15
Still open: $15M

Investors: 15
Sector: Biotech
HQ: Cambridge, MA

NextPoint Therapeutics filings

NextPoint Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Jul 30, 2026	Equity	$33.7M/ $48.7M	Form D

EquityFiled Jul 30, 2026Form D
$33.7M/ $48.7M

Works with

Also named on NextPoint Therapeutics filings

Jeffrey LaceySecretary & Treasurer, Form D signerForm D signer Paulina HillDirector Axel HoosDirector Brian ShusterDirector Detlev BiniszkiewiczDirector Ivan CheungExecutive Officer, Director Rakhshita DharDirector